Journal
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
Volume 21, Issue 4, Pages 629-637Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.beha.2008.08.003
Keywords
targeted agents; histone deacetylase inhibitors; HDAC; NF-kappa B inhibitors; CDK inhibitors; proteasome inhibitors; MEK inhibitors; BCL-2 inhibitors
Categories
Funding
- NCI NIH HHS [R01 CA093738, R21 CA110953, P50 CA130805, R01 CA100866, RC2 CA148431, R21 CA137823, P50 CA142509] Funding Source: Medline
Ask authors/readers for more resources
The concept of combining targeted agents for the treatment of acute myeloid leukemia (AML) is a relatively new but potentially promising area of investigation. A number of targeted agents may have limited single-agent activity but Could show significant promise when used in conjunction with other types of similar compounds. Combinations of targeted agents may effectively interrupt multiple pathways in either a linear or parallel fashion. There are currently numerous combination regimens under investigation at either the preclinical or clinical levels, including histone deacetylase (HDAC) and CDK inhibitors; HDAC and proteasome inhibitors; HDAC and NF-kappa B (IKK beta) inhibitors; CHK1 and MEK 1/2 inhibitors; and BCL-2 antagonists and CDK inhibitors. Although combinations of targeted agents will not displace conventional cytotoxic regimens in AML or related disorders in the foreseeable future, these combinations clearly warrant further attention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available